Cancer
50 stories · Page 3 of 3
Cancer
Ozempic's 30 Percent Breast-Cancer Headline, and the Trial Evidence It Walked Past
A single-system observational study at ASCO 2026 attached a roughly 30% lower breast-cancer rate to GLP-1 use. The randomized record already on the table is quieter.
CancerPancreatic cancer's undruggable wall just cracked. The follow-up is 8.5 months and the money was already placed.
Revolution Medicines' daraxonrasib nearly doubled median overall survival versus chemotherapy in previously treated metastatic pancreatic cancer at ASCO 2026, with 8.5 months of follow-up and a two-billion-dollar Royalty Pharma deal already riding on what comes next.